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We applied peptide array methylation to determine
an optimized target sequence for the SET7/9
(KMT7) protein lysine methyltransferase. Based on
this, we identified 91 new peptide substrates from
human proteins, many of them better than known
substrates. We confirmed methylation of corre-
sponding protein domains in vitro and in vivo with
a high success rate for strongly methylated peptides
and showed methylation of nine nonhistone proteins
(AKA6, CENPC1, MeCP2, MINT, PPARBP, ZDH8,
Cullin1, IRF1, and [weakly] TTK) and of H2A and
H2B, which more than doubles the number of known
SET7/9 targets. SET7/9 is inhibited by phosphoryla-
tion of histone and nonhistone substrate proteins.
One lysine in the MINT protein is dimethylated
in vitro and in vivo demonstrating that the product
pattern created by SET7/9 depends on the amino
acid sequence context of the target site.
INTRODUCTION
SET7/9 (KMT7) is a protein lysine methyltransferase (PKMT) that
had been initially identified as a histone lysine methyltransferase
which generates monomethylation at histone 3 lysine 4 (Wang
et al., 2001; Xiao et al., 2003). The function of SET7/9 is not clear:
on one hand, it plays a role in regulating euchromatic gene
expression through H3K4 methylation (Brasacchio et al., 2009;
Chakrabarti et al., 2003; Deering et al., 2009; Evans-Molina
et al., 2009; Subramanian et al., 2008); on the other hand, it
was shown that SET7/9 exhibits very weak activity on nucleo-
somal substrates (Wang et al., 2001), suggesting that the main
function of SET7/9 is nonhistone protein methylation. Indeed,
SET7/9 methylates several nonhistone proteins such as
Dnmt1, p53, TAF10, estrogen receptor a, pRb, p65, and Tat
protein of HIV1 (Chuikov et al., 2004; Couture et al., 2006; Ea
and Baltimore, 2009; Kouskouti et al., 2004; Kurash et al.,
2008; Munro et al., 2010; Pagans et al., 2010; Subramanian
et al., 2008; Wang et al., 2009). Different functions wereChemistry & Biology 18, 111attributed to the protein methylation mediated by SET7/9. For
example, methylation of Dnmt1 by SET7/9 reduces its stability
(Wang et al., 2009), whereas methylation of p53 and estrogen
receptor a (ER) leads to their activation and stabilization (Chuikov
et al., 2004; Kurash et al., 2008; Subramanian et al., 2008).
Methylation of TAF10 by SET7/9 increases the affinity of TAF10
for RNA polymerase II and thereby helps in the formation of the
preinitiation complex (Kouskouti et al., 2004).
The methylation activity of SET7/9 toward different substrates
suggests a relaxed specificity of the enzyme. Crystal structures
of peptides from histone H3, p53, and TAF10 bound to SET7/9
indeed revealed a considerable plasticity in its peptide interac-
tion (see Table S1 available online) (Chuikov et al., 2004; Couture
et al., 2006; Subramanian et al., 2008; Xiao et al., 2003). From the
crystal structures, it had been proposed that SET7/9 mainly
recognizes the sequence motif [KR] [STA] K (in which the
methylation site is underlined) in the target peptide (Couture
et al., 2006). However, this motif is based on only very few known
targets, which often were identified by similarity to each other
and to the original H3K4 site. Here, we have determined the
specificity profile of SET7/9 in a stepwise iterative approach by
methylating a series of peptide arrays, which altogether
comprised more than 1200 different peptides. By using the
derived specificity profile of SET7/9, we identified more than
90 new nonhistone target peptides and also show strong
methylation of H2A and H2B tails. SET7/9 methylated many of
the new nonhistone target peptides much stronger than its
known targets. We investigated the methylation of 12 new target
proteins and demonstrated that SET7/9 methylates 9 proteins
in vitro and 5 proteins in vivo. We have also shown that the
product spectrum of SET7/9 depends on the nature of the
substrate and that dimethylation is produced with a better
substrate. In addition, we investigated the influence of modifica-
tions at the H3 peptide on enzyme activity in an unbiased
approach and show that phosphorylation of histone and nonhis-
tone substrates inhibit methylation by SET7/9.
RESULTS
Specificity Profile of SET7/9
To analyze the substrate specificity of SET7/9, we prepared
histone H3 tail (1-21) peptide arrays on functionalized cellulose
membranes by SPOT peptide synthesis (Frank, 2002; Reineke–120, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 111
Figure 1. Specificity Analysis of Human
SET7/9
(A) On the H3 tail 1-21 peptide each residue was
exchanged against all 20 natural amino acid resi-
dues and the relative methylation by SET7/9
analyzed. Data are averaged numbers from three
independent experiments. Methylation activities
were normalized relative to methylation activity of
SET7/9 on the natural H3 peptide.
(B) Relative methylation activity of SET7/9 on H3
tail peptides when T3 is exchanged with all other
amino acids. The coloring scheme is based on
relative activity (>1.2 orange, 1.2–0.8 green, 0.8–
0.5 light blue, and <0.5 dark blue). Error bars
represent standard deviations of three indepen-
dent experiments.
(C) Two site randomization array where the K9 and
G12 residues (2 and +1 position) were
exchanged against all 20 natural amino acid resi-
dues on the modified H3 T11K tail backbone
(which is methylated at K11). Methylation activities
were normalized relative to themethylation activity
of SET7/9 on wild-type H3 peptide.
(D) Two site randomization array where the R8 and
G13 residues (3 and +2 positions) were
exchanged against all 20 natural amino acid resi-
dues on the modified H3 T11K G12Q tail (with
central KSKQ sequence with target K underlined).
The rawdata for this figureareprovided inTableS4.
See also Figure S1 and Table S1.
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SET7/9 Specificity and Novel Substrateset al., 2001). In these arrays, each residue of the H3 tail was
exchanged against all other 20 natural amino acids. The
membranes containing the peptide arrays were incubated with
purified SET7/9 enzyme in the presence of radioactively labeled
S-adenosyl-L-methionine (AdoMet) and the transfer of the
methyl group to the peptides on the membrane was detected
by autoradiography. As expected, an exchange of the target
lysine K4 of the H3 tail sequence with any other amino acid led
to the complete loss of enzyme activity (Figure 1A). Specific
sequence readout by SET7/9 was observed in the region
between A1 and T6. However, we identified three spots, which
were methylated much stronger by SET7/9 than the natural H3
1-21 peptide (Figure 1A). This effect was reproducible in different
experiments using independently synthesized peptide arrays as
substrates. One of these high activity peptides corresponded to
H3 tail peptide in which T3 is exchanged with serine and the
second one corresponded to the H3 T11K variant. The common
feature of these two spots is the generation of a [KR] S K motif
that is not present in the natural H3 tail sequence. In the first
case, the T3S exchange places the K4 into an RSK context
and in the second case the T11K exchange created a new
KSK site with the new K11 as target. A third spot with increased
activity is the A1S variant that can be understood in the light of
data presented below.
A comparison of the methylation observed at all peptides in
which T3 was exchanged (this residue corresponds to the 1
position, if the target lysine is considered position 0) showed
that many residues are tolerated at this place (Figure 1B), but
only S led to an increase in activity. With A, R, N, K, P, and Y,
we observed activity similar (±20%) to T which is originally
present at this place. Only D, E, G, I, and L led to a >50% reduc-
tion of activity.112 Chemistry & Biology 18, 111–120, January 28, 2011 ª2011 ElsevThe preference for [KR] S K motifs suggested that the real
specificity of SET7/9 differs from the H3 template, stimulating
us trying to identify an ‘‘optimized’’ target sequence. To this
end, we have kept the SK motif as a main recognition motif in
the H3 tail T11K sequence context (which gets methylated at
the newly introduced K11) and exchanged the 2 position
and +1 position against all other amino acids to cover all possible
combinations of 2 and +1 residues. The highest activity was
observed when R or K was introduced at the 2 position and
Q or N was substituted at the +1 position. The enzyme showed
moderate activity when the +1 position was substituted with all
amino acids except F, Y, W, P, or L (Figure 1C). This result is
summed up by the following motif:
[K > R] [S > KYARTPN] K [QN > other aa but not FYWPL]
Based on these results, we further extended the substrate
specificity profile by keeping KSKQ as main recognition motif
and exchanged the 3 and +2 positions with all other amino
acids. The strongest activity of SET7/9 was observed when G
is placed at the 3 position and moderate activity was also
seen with R, H, K, P, S, or T at this position (Figure 1D). For
position +2 the main result was that D, E, L, W, or Y inhibit
methylation. By combining all the results from the different
peptide array experiments, we derived two specificity profiles
for the SET7/9 enzyme as:
G [K > R] [S > KYARTPN] K [QN > other aa but not FYWPL] [not
DELWY] or
[RHKPST] [K > R] [S > KYARTPN] K [QN > other aa but not
FYWPL] [AQGMSPTYV]
which may be combined as: [GRHKPST] [K > R] [S > KYA
RTPN] K [QN] [AQGMSPTYV]
This result includes the published specificity profile (Couture
et al., 2006), but it shows important expansions and someier Ltd All rights reserved
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Figure 2. In Vitro Methylation of New Substrate Peptides and Proteins
(A) Comparison of the peptide methylation activity of SET7/9 on several known and newly identified substrates (the complete list of peptide substrates and meth-
ylation activities is available in Figure S2).
(B) Detection of protein methylation by transfer of radioactively labeled methyl groups. Purified GST-tagged protein domains were incubated with SET7/9 in the
presence of radioactively labeled [methyl-3H]-AdoMet and separated on an SDS polyacrylamide gel, and the methylation of the target proteins was analyzed by
autoradiography. As a control, methylation of histone H3 is shown. Methylated proteins are labeled in black color, not (or only very little) methylated proteins
in gray.
(C) Identification of the modified lysine. The wild-type target proteins and the mutant proteins in which the target lysine residue was exchanged by arginine were
methylated by SET7/9 using radioactive AdoMet.
(D) Alignment of some known and novel SET7/9 targets. The shading represents the agreement with the specificity profile.
See also Figure S3.
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SET7/9 Specificity and Novel Substrateschanges in detail. The clear preference for S over A at position
3 explains the high methylation of the H3 tail A1S variant
mentioned before (Figure 1A).
Interestingly, the enzyme also showed high activity when
cysteine was introduced simultaneously at the 3 and +2 posi-
tions (Figure 1D). This observation fits with the reported cocrystal
structures of SET7/9 together with H3 peptide because the
cysteines at positions 3 and +2 are located in a Ca distance
of 5.5 A˚ (Figure S1). In the complex the target peptide forms
a loop that could be covalently connected if the two cysteine
residues form a disulfide bond. Thereby, the loop will be stabi-
lized, which could explain better methylation by SET7/9.
SET/9 Methylates New Nonhistone target
Peptides In Vitro
As described above, the sequence preferences of SET7/9 do not
fully match the H3 peptide and some of the already identified
nonhistone targets. Therefore, we were interested to investigate
if the methylation of identified SET7/9 substrates agrees with our
findings. We synthesized peptides corresponding to H3, p53,
TAF10, DNMT1, ER, TAT, and p65 and investigated their methyl-
ation by SET7/9 and observed that TAF10 is the best substrateChemistry & Biology 18, 111among them (Figure 2A; Figure S2). Next, we wanted to identify
additional nonhistone substrates of SET7/9. To this end, a Scan-
site search (http://scansite.mit.edu/) was conducted using
our SET7/9 specificity profiles which retrieved more than
400 human proteins containing potential target sites. Out of
these, 118 proteins with known or predicted nuclear localization
were selected for further analysis. In total, we have synthesized
133 peptides (derived from the 118 proteins) in duplicates
and tested for methylation by SET7/9 on cellulose membranes
(Figure 2A; Figure S2). It was observed that 44 peptides
got strongly methylated, 47 peptides got weakly methylated
and 42 peptides were not methylated by SET7/9. Since methyl-
ation of several substrates is performed in competition on
the SPOTmembranes, themethylation levels of different peptide
spots correspond to kcat/KD values, which is a well-established
measure of enzyme specificity (see Supplemental Information
S1 in Rathert et al., 2008b). Hence, we conclude that the
new peptides were methylated stronger than most of the
previously known SET7/9 targets when presented on cellulose
surface. We confirmed the stronger methylation of the
MINT peptide than H3 peptide in solution as an example (see
below).–120, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 113
H2A
H2BH2A Control
H2B unmodified or K5Ac or K12Ac 
H2B S14P 
H2B K15Ac 
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Figure 3. SET7/9 Activity on H2A and H2B N-Terminal Tails
(A) Methylation of H2A and H2B peptides containing different combinations of
PTMs by SET7/9 (Table S3).
(B) Methylation of recombinant H3, H2A and H2B proteins. The histone
proteins were incubated with SET7/9 in the presence of radioactively labeled
[methyl-3H]-AdoMet and separated on an SDS polyacrylamide gel. The meth-
ylation of the target proteins was analyzed by autoradiography.
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SET7/9 Specificity and Novel SubstratesThemethylation levels of the different peptides showed a clear
correlation with the net charge of the peptide, with positive
charge increasing the methylation activity (Figure S3A). This
result is in agreement with the observation that the substrate
binding pocket of SET7/9 is flanked by many acidic residues
(Figure S3B). The preference for positively charged substrates
may also explain the weak methylation of H3 on nucleosome
substrates (Wang et al., 2001) where the charge of the H3 tail
is compensated by the bound DNA. A close inspection of the
activities observed with the tested peptides suggests that the
presence of the KSKmotif embedded in a context of basic amino
acid residues appears to be the most important parameter for
SET7/9 activity.
SET/9 Methylates New Nonhistone target
Proteins In Vitro
The peptidemethylation assay is taking place on peptides bound
to hydrated cellulose fibers which might influence reaction
kinetics. Furthermore, the newly identified peptide substrates
may not be accessible in the context of the target proteins.
Therefore, it was important to investigate if nonhistone
substrates were also methylated at the protein level. Fourteen
target peptides were selected based on their high methylation
and the corresponding protein domains cloned into a GST
expression vector. The candidate nonhistone target protein
domains were overexpressed and purified by affinity chromatog-
raphy (Figure 2B). Out of the 14 target candidate protein
domains, 12 got expressed well and could be purified. The
protein domains from PRP4 and CRKRS failed in expression.
The methylation of the purified proteins by SET7/9 was analyzed
by incubating the protein domains with SET7/9 enzyme in a reac-
tion buffer containing radioactively labeled AdoMet. The
substrate protein domains were separated from radioactive
cofactor and enzyme by SDS-PAGE. The methylation activity
of SET7/9 on these protein domains was analyzed by measuring
the transfer of radioactive methyl groups to the protein domains
by autoradiography. Out of the 12 target protein domains, 9 were
methylated by SET7/9, viz. AKA6, CENPC1, MeCP2, MINT,
PPARBP, ZDH8, Cullin1, IRF1, and (weakly) TTK (Figure 2B).
We have also included recombinant histone 3 as a positive
control showing that many of the new nonhistone target domains
were methylated by SET7/9 more efficiently than histone 3. The
high yield of successful prediction of peptide and protein targets
demonstrates the power of our peptide array-based specificity
profile approach.
Site-directedmutagenesis was performed in the target protein
domains to determine which lysine is methylated by SET7/9. To
this end, the putative target lysines identified on the basis of the
specificity profile of SET7/9 were exchanged to arginine. The
mutated proteins were expressed and analyzed for methylation
by SET7/9 (Figure 2C). SET7/9 showed no or strongly reduced
activity on all mutant proteins confirming that they were methyl-
ated at the expected target lysine as predicted by the specificity
profile of the SET7/9. In case of MeCP2, PPARBP, and IRF1,
weak methylation was seen even after mutation of the predicted
target lysine suggesting the presence of a second (weaker)meth-
ylation site in addition to the predicted target lysine. However,
from the comparison of the intensities it is clear that our predicted
target lysine is the primary target for SET7/9 in all three of these114 Chemistry & Biology 18, 111–120, January 28, 2011 ª2011 Elsevproteins (Figure 2C). Methylation of most target lysine residues
was also confirmed by mass spectrometry (data not shown).
SET7/9 Methylates H2A and H2B Tails
It was recently shown that NSD2methylates histone 4 in addition
to the originally identified histone 3 target (Li et al., 2009).
Similarly, G9a and GLP methylate histone H1 in addition to the
initially identified histone 3 target (Rathert et al., 2008a; Weiss
et al., 2010). However, the methyltransferase activity of SET7/9
toward other histone tails has not yet thoroughly studied. To
this end, we methylated a histone tail peptide array with SET7/
9. While only weak methylation was observed on the H4 tail
(data not shown) strong methylation occurred on H2A and H2B
(Figure 3A). Recombinant full-length H2A and H2B were also
methylated by SET7/9 and their methylation efficiency is compa-
rable with H3 methylation (Figure 3B).
Strong methylation of both H2A and H2B is not unexpected,
since both are very basic (H2A: SGRGKQGGKARAKAKSRSS,
net charge+7;H2B: PDPAKSAPAPKKGSKKAVT, net charge+4).
The results with the peptide array suggest that SET7/9 methyl-
ates multiple lysines on H2A tail, since the acetylation of one or
more lysine in these tails could not inhibit the SET7/9 activity
(Figure 3A). This conclusion was confirmed by methylation
studies with H2A tail variants in which all lysine residues were
individually exchanged by alanine (data not shown). Multiple
methylation sites in H2A are in agreement with having several
lysine residues in H2Awhich are in a sequence context favorable
for methylation, viz. K5 (R G K), K13 (R A K) and K15 (K A K). In
contrast, K15 is the primary target lysine on H2B, since the acet-
ylation of K15 blocks most of the SET7/9 activity while acetyla-
tion of other lysines (K5 and K12) had little influence (Figure 3A).
Having K at position +1 and S at position 1, the sequence
context of K15 of H2B fits to the specificity profile of SET7/9.
SET/9 Methylates New Nonhistone Targets In Vivo
Themethylation of the nine new nonhistone protein domains was
analyzed in human HEK293 cells by coexpression of the SET7/9ier Ltd All rights reserved
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Figure 4. In Vivo Methylation of New Nonhistone Target Proteins by SET7/9
YFP-tagged target proteins were transiently expressed together with SET7/9 in HEK293 cells, immunoprecipitated and the peptides obtained after tryptic digest
were subjected to mass spectrometry analysis. The sequences and theoretical masses of identified peptides are given below the spectra. Methylated peptides
were not detected without coexpression of SET7/9 (Figure S7).
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SET7/9 Specificity and Novel Substratesenzyme and the target protein domains. The YFP fused target
protein domains were purified from the cells by immunoprecipi-
tation and separated by SDS gel electrophoresis. The corre-
sponding gel pieces containing the target protein bands were
cut out, the proteins in gel-digested with trypsin and the methyl-
ation state of the respective target peptides analyzed by mass
spectrometry. It was found that five of the target protein domains
(CENPC1, IRF1,MeCP2,MINT, and ZDH8) gotmethylated inside
the human cells when they were coexpressed with SET7/9 but
not without coexpression (Figure 4; Figure S7). In case of the
four other proteins, we could not detect the peptide containing
the target lysine (neither in methylated nor in unmethylated
state), and hence we could not determine their methylation
status. These results confirm that SET7/9 methylates many of
the new targets in vivo.
The MALDI mass spectrometry analysis of MeCP2, IRF1, and
MINT revealed that two methyl groups were transferred to
the tryptic peptide containing the target lysine, suggesting either
dimethylation of the target or monomethylation of two indepen-Chemistry & Biology 18, 111dent lysines (Figure 4). This result agrees with the observation of
a second methylation site in the in vitro experiment with MeCP2
and IRF1, which rules out the possibility of dimethylation. The
presence of a secondmethylation site in IRF1 could be explained
since it has two KSK motifs nearby. In case of MINT, mutagen-
esis of the KSK lysine (lysine 2076 of MINT) led to a complete
loss of all methylation suggesting that this residue is dimethy-
lated by SET7/9 in cells. Dimethylation of the MINT substrate
was confirmed at peptide level as described in the next
paragraph.
SET7/9 Product Profile Depends on the Substrate
Peptide Sequence
In various studies, the SET7/9 enzyme has been described as
a monomethyltransferase (Wang et al., 2001; Xiao et al., 2003;
Zhang et al., 2003), and molecular modeling has been applied
to explain this product specificity (Guo and Guo, 2007; Zhang
and Bruice, 2008). Mutagenesis of Y305F converted the enzyme
into a di- and trimethyltransferase (Zhang et al., 2003) leading to–120, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 115
Figure 5. Methylation Kinetics of H3 and aMINT Peptide Variant that
Contained Only One Lysine Residue (A N S R S K R G R S R N S A)
H3 peptide and MINT peptide were methylated in competition by SET7/9 and
the time course of the reaction by analyzing the products inmass spectrometry
at different time points. The relative area of the peaks of the unmethylated
(black), monomethylated (dark gray), and dimethylated peptides (light gray)
of H3 and MINT were calculated and the data fitted to a distributive two-
step methylation process. The fit is shown as solid line (see Figure S4A for
primary data). The linear response of the peak area to peptide fractions in
the mass spectrometric analyses was confirmed by a calibration experiment
(Figure S4B). Error bars were estimated on the basis of two repeats of the
experiment and of the results of the calibration experiment.
Chemistry & Biology
SET7/9 Specificity and Novel Substratesthe identification of a similar Tyr/Phe switch in many related
enzymes (Collins et al., 2005; Couture et al., 2008; Takahashi
et al., 2009; Zhang et al., 2003). As described above, our mass
spectrometric analysis of the MINT target provided evidence
that dimethylation is introduced into this peptide. To compare
the methylation kinetics and product specificity of SET7/9 for
the H3 and the MINT peptide, we have synthesized a version
of the MINT peptide which contains only one lysine, methylated
this peptide together with the H3 peptide in competition in one
reaction tube and followed the time course of the reaction by
analyzing the products by mass spectrometry at different time
points. In this experimental setup and under multiple turnover
conditions, the partitioning of the enzyme between the both
substrates is determined by the ratio of the KD-values and
turnover is given by kcat. Hence, the relative rates of methylation
of both substrates correspond to kcat/KD, which is a well-
established criterion to assess enzyme specificity and activity.
We opted for the competitive methylation design because of
several advantages: (1) the absolute concentrations of the
substrates are not relevant as long as multiple turnover is
ensured. (2) Potential pipetting inaccuracies in enzyme and
cofactor addition are equally affecting both reactions. (3) Poten-
tial synthesis by-products or contaminants affect both reactions
equally. However, this design does not allow for direct measure-
ment of the individual Km and kcat values.
The mass spectrometric analysis revealed that after 6 hours of
methylation by SET7/9, only 10% of the H3 peptide was dime-
thylated, while in case of MINT peptide nearly 50%was dimethy-
lated (Figure 5; Figure S4). However, monomethylated peptides
were the main products in the initial time points indicating
a nonprocessive reaction mechanism. Fitting to a distributive
methylation reaction revealed that the first and second methyl
group transfer reactions are about 5-fold faster with the MINT
peptide as compared to H3. It is interesting to note that the
improved methylation of the MINT peptide was observed even
after the K to R exchange at pos. 2, which was necessary for
technical reasons to demonstrate dimethylation of one single
K residue. According to our results, the original MINT peptide
is expected to be an even better substrate. Better methylation
of the modified MINT peptide can be attributed to the S residues
positioned at 3 and 1, which are both preferred over A and
T found in the H3 peptide at the corresponding sites. Most
importantly this analysis reveals that the number of methyl
groups introduced by the SET7/9 enzyme depends on the
sequence of the substrate peptide.
SET7/9 Activity Is Inhibited by Phosphorylation of the
Substrate Peptide or Protein
It is of importance if other modifications influence the activity of
SET7/9. On the H3 peptide, it was reported that the SET7/9
activity is reduced by H3K9 trimethylation (Wang et al., 2001)
and H3R2 methlyation (Couture et al., 2006). Phosphorylation
was shown to inhibit SET7/9 on H3 and the p53 peptide (Couture
et al., 2006). In the context of the ER peptide, acetylation of the
K at +1 position has been shown to reduce enzyme activity
(Subramanian et al., 2008). To study the interference of different
modifications on methylation activity of SET7/9, a modified
CelluSpot peptide array was methylated by SET7/9 in the
presence of radioactively labeled AdoMet (Figure 6A). The array116 Chemistry & Biology 18, 111–120, January 28, 2011 ª2011 Elsevcontained 216 peptides derived from the N-terminal tail of H3
featuring 18 different PTMs in many combinations. Among the
H3 peptides, we observed the SET7/9 methylation activity
was inhibited by H3K4me1, H3K4me2, H3K4me3, and H3K4
acetylation, which confirms the earlier findings that SET7/9 is
a monomethyltransferase on the H3 substrate (Figure 4A; Table
S2) (Wang et al., 2001; Xiao et al., 2003). We did not observe an
inhibition of SET7/9 activity by H3K9 trimethylation, which is in
agreement with the finding that K9 is not contacted by the
enzyme in the crystal structure (Xiao et al., 2003). We also
observed that symmetric or asymmetric methylation of R2 of
the H3 tail has no influence on SET7/9 activity (Figure 4A), which
is in agreement with the weak contact to R2 observed in the
structure. However, phosphorylation of T3, S10, or T11 on the
H3 tail abolished the SET7/9 activity completely, which is in
line with the general preference of SET7/9 for positively charged
substrates mentioned before. Similarly, S14 phosphorylation of
H2B (next to the main target K15) inhibited the methylationier Ltd All rights reserved
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Figure 6. SET7/9 Is Inhibited by Phosphorylation of the Target
Peptide or Protein
(A) Relative activity of SET7/9 on CelluSpot array derived from H3 peptides
containing different combinations of PTMs (Table S2). Phosphorylation of
T3, S10, and T11 abolished SET7/9 activity.
(B) Influence of phosphorylation of nonhistone substrates on SET7/9 methyla-
tion activity. GST-tagged nonhistone substrates of SET7/9 were incubated
with PKA. All domains except Cullin1 were phosphorylated (Figure S5).
Then, phosphorylated and mock treated domains were methylated by
SET7/9. A complete loss or strong reduction of SET7/9 activity was observed
with ZDN8, IRF1, MINT, PPARBP, and MeCP2.
See also Figure S6.
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SET7/9 Specificity and Novel Substratesactivity of SET7/9which underscores the general inhibitory effect
of substrate phosphorylation on SET7/9 (Figure 3A).
To investigate the effect of the phosphorylation of nonhistone
proteins on SET7/9 activity, we used GPS2.0 (Xue et al., 2008)
to predict kinases that could act on the protein domains.
This analysis revealed that most of the nonhistone protein
domains are potential substrates for several major kinases
including protein kinase A (PKA). Therefore, we incubated the
GST-tagged nonhistone substrateswith PKA and observed clear
phosphorylation of all domains except Cullin1 (Figure S5). The
phosphorylated and mock treated domains were methylated
by SET7/9 revealing a complete loss or strong reduction of
SET7/9 activity after phosphorylation of ZDN8, IRF1, MINT,
PPARBP, and MeCP2 (Figure 6B). We investigated the target
protein domains isolated from HEK293 cells after coexpression
of the SET7/9 enzyme and the target protein domains for poten-
tial phosphorylation next to the target lysine by mass spectrom-
etry. Phosphorylation within the tryptic peptides that contain the
target lysine was observed for IRF1 and MINT (Figure S5).
However, we could not detect target peptides containing both
the methylation and phosphorylation marks suggesting that
phosphorylation inhibits SET7/9 methylation in vivo as well.Chemistry & Biology 18, 111These results indicate that the SET7/9 signaling pathway is
tightly connected to protein phosphorylation.
DISCUSSION
Peptide arrays are ideal tools to investigate the specificity of
PKMTs, because they allow determining the enzymatic activity
for more than 400 different substrates in a single experiment in
competition. It is also possible to design partially randomized
arrays of peptides based on an initial sequence motif to find un-
predicted new substrate specificities. The peptide array-based
approach was successfully used in our lab previously to identify
new targets for G9a and to study the specificity of Dim5 (Rathert
et al., 2008a, 2008b). In the present study, we discovered an
optimized target sequencemotif for SET7/9 in a series of peptide
array methylation experiments in total including more than 1200
different peptides. Based on our specificity profile, we identified
91 new target peptides, about one-third of which were better
substrates for SET7/9 than the originally described histone 3
target. We confirmed methylation of selected strongly methyl-
ated candidate peptides at the protein domain level in vitro
and in vivo with a high success rate suggesting that there are
many more methylation substrates of SET7/9 are among our
list of peptide substrates. Altogether, we show methylation of
nine nonhistone proteins plus methylation of H2A and H2B,
which more than doubles the number of known SET7/9 targets.
Methylation of H2A and B had not been observed with histone
octamers (Wang et al., 2001), suggesting that only free H2A
and B are substrates for SET7/9. This situation is comparable
with NSD2, which methylates the free H4 protein but not in the
context of nucleosomes (Li et al., 2009). It is known that a fraction
of histone H3 and H4 carry some modifications prior to their
incorporation into chromatin (Barth and Imhof, 2010). Whether
methylation of free H2A and H2B histone proteins by SET7/9
occurs and if it has a physiological role remains to be seen.
A comparison of known and novel SET7/9 substrates
(Figure 2D) with the combined specificity profile [GRHKPST]
[K > R] [S > KYARTPN] K [QN] [AQGMSPTYV] indicates that all
targets follow the profile at the 1 and 2 positions (Figure 2D).
Position 3 also applies often, while the +1 and +2 positions
appear less important suggesting that a [GRHKPST] [K > R]
[S > KYARTPN] K motif will be most appropriate to search for
additional SET7/9 substrates. It is important to note that
peptides not ideally matching this sequence (like some of the
previously known SET7/9 targets) can be methylated as well,
although methylation often is weaker at peptide level (see, for
example, Dnmt1, ER, Tat, or p65 in Figure 2A). Additional target
Set7/9 sites were identified that do not follow the consensus,
including NF-kappaB p65 K314 and K315 (Yang et al., 2009),
Rb K873 (Munro et al., 2010), and several methylation sites in
PCAF (Masatsugu and Yamamoto, 2009). However, these sites
were all methylated with lower efficiency than H3K4, while strong
targets identified here, which follow the consensus, all are meth-
ylated better than H3K4. Weaker methylation does not rule out
important biological roles of these methylation events, because
in the cell a strong interaction of a target protein with the
SET7/9 enzyme may stimulate methylation of weak target sites.
We have shown that the SET7/9 activity on histone tails and
nonhistone substrates is inhibited by serine phosphorylation–120, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 117
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SET7/9 mediated methylation of histone and nonhistone
proteins as previously shown for E2F1 (Kontaki and Talianidis,
2010). Monomethylation of lysine directly blocks its acetylation,
but it may also influence acetylation of remote sites in a more
complex manner. SET7/9 methylation is necessary for it subse-
quent acetylation by Tip60 (Ivanov et al., 2007; Kurash et al.,
2008), but it inhibits acetylation of E2F1 (Kontaki and Talianidis,
2010). In cells, SET7/9 methylation has been shown to increase
stability of p53 (Chuikov et al., 2004) but decrease Dnmt1
stability (Esteve et al., 2009; Wang et al., 2009).SIGNIFICANCE
SET7/9 (KMT7) is a protein lysine methyltransferase (PKMT)
that had been initially identified as a histone H3 lysine-4
monomethyltransferase, but nonhistone substrates of this
enzymewere discovered later. In the present study we apply
peptide array methylation to determine an optimized target
sequence motif for SET7/9 as [GRHKPST] [K > R] [S > KYA
RTPN] K (with the target lysine underlined) surrounded by
basic amino acid residues. Based on this, we discover 91
new peptide SET7/9 substrates and show methylation of
nine nonhistone proteins (AKA6, CENPC1, MeCP2, MINT,
PPARBP, ZDH8, Cullin1, IRF1, and [weakly] TTK) plus meth-
ylation of H2A and H2B, which more than doubles the
number of known SET7/9 targets. Our results contribute to
the emerging picture that lysinemethylation is a widespread
posttranslational modification. Our data document that
novel PKMT substrates, which are methylated better than
previously known substrates, can be identified following
an unbiased approach. We show that SET7/9 is inhibited
by phosphorylation of histone and nonhistone substrate
proteins indicating that nonhistone protein methylation by
SET7/9 is connected to other signaling pathways like phos-
phorylation and acetylation. Finally, we show that one lysine
residue in theMINT protein is dimethylated by SET7/9 in vitro
and in vivo demonstrating that the product spectrum of
PKMTs depends on the nature of the substrate. This finding
adds another level of complexity to the function of PKMTs.EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Proteins
The sequence encoding human A kinase anchor protein 6 (AKA6) (residues
485–776; NCBI accession number NP_004265.3), Bromodomain containing
1 (BRD1) (residues 681–891; NCBI accession number NP_055392.1), Centro-
meric protein C1 (CENPC1) (residues 279–474; NCBI accession number
NP_001803.2), Dnmt1 (residues 622–780; NCBI accession number
NP_001370.1), Methyl CpG binding protein 2 (MeCP2) (residues 201–486;
NCBI accession number NP_004983.1), Msx2-interacting protein (MINT)
(residues 1994–2281; NCBI accession number NP_055816.2), PPAR
binding protein (PPARBP) (residues 847–1084; NCBI accession number
NP_004765.2), Retinoblastoma binding protein 5 (RBBP5) (residues 323–
538; NCBI accession number NP_005048.2), Zinc finger DHHC domain
containing 8 (ZDHHC8) (residues 227–400; NCBI accession number
NP_037505.1), PRP4 pre-mRNA processing factor 4 homolog B (PRP4) (resi-
dues 93–396; NCBI accession number NP_789770.1) CDC2 related protein
kinase 7 (CRKRS) (residues 2–339; NCBI accession number NP_057591.1),
Cullin1 (residues 2–250; NCBI accession number NP_003583.2), TTK (residues
603–799; NCBI accession number NP_003309.2), and IRF1 (residues 71–240;118 Chemistry & Biology 18, 111–120, January 28, 2011 ª2011 ElsevNCBI accession number NP_002189.1) were amplified from HEK293 cDNA
and cloned into pENTR/D-TOPO (Invitrogen) gateway entry vector according
to the manufacturer’s instructions. pGEX-6P-2 vector (GE healthcare) was
converted into Gateway destination vector (pGEX-6P-2-GW-AJ) using
Gateway vector conversion system (Invitrogen). The cloned genes from the
pENTR/D-TOPO were subcloned into pGEX-6P-2-GW-AJ using LR recombi-
nation system (Invitrogen) according to the manufacturer’s instructions.
For mammalian expression, an oligonucleotide coding for the nuclear local-
ization signal of simian virus large T-antigen was cloned in frame with YFP
protein in pEYFP-C1 vector (Clontech) by using BspEI/XhoI sites to generate
the pEYFP-C1-AJ-NLS construct. The target protein domains were subcloned
into pEYFP-C1-AJ-NLS by using XhoI/EcoRI sites except AKA6. The protein
domain of AKA6 was subcloned into pEYFP-C1-AJ-NLS by using XhoI/BamHI
site. The full-length SET7/9 enzyme was subcloned into pCDNA4/myc-His
vector (Invitrogen) using BamHI/XhoI sites.
The K604R mutation in AKA6, K414R mutation in CENPC1, K347R mutation
in MeCP2, K2076R mutation in MINT, K1006R mutation in PPARBP, K300R
mutation in ZDH8, K73R mutation in Cullin1, K708R mutation in TTK, and
K126Rmutation in IRF1 were introduced using PCR-megaprimer mutagenesis
method as previously described (Jeltsch and Lanio, 2002). Mutagenesis was
confirmed by restriction marker site analysis and DNA sequencing.
For expression, Escherichia coli BL21 (Novagen) carrying corresponding
plasmid were grown in Luria-Bertani medium at 37C to OD600 z0.6,
then shifted to 22C for 20 min and induced overnight with 1 mM isopropyl
b-D-thiogalactoside. The cells were collected by centrifugation and resus-
pended in 20 mM HEPES (pH 7.5), 0.5 M KCl, 0.2 mM DTT, 1 mM EDTA,
and 10% glycerol and disrupted by sonication. The supernatants were passed
through glutathione Sepharose 4B resin (Amersham Biosciences) and washed
with same buffer. The bound proteins were elutedwith similar buffer containing
40 mM glutathione and dialyzed in 20 mM HEPES (pH 7.5), 0.2 M KCl, 0.2 mM
DTT, 1 mM EDTA, and 10% glycerol for 2 hr and then overnight in 20 mM
HEPES (pH 7.5), 0.2 M KCl, 0.2 mM DTT, 1 mM EDTA, and 60% glycerol.
The SET7/9 expression construct pXC367 was kindly provided by Prof.
Xiodong Cheng. The SET7/9 enzymewas expressed and purified as described
(Zhang et al., 2003). Recombinant histone 3 (3.1), histone H2A, and histone
H2B were purchased from New England Biolabs.
Synthesis of Peptide SPOT Arrays
Peptide arrays were synthesized using the SPOT synthesis method (Frank,
2002; Wenschuh et al., 2000). Each spot had a diameter of 2 mm and con-
tained approximately 9 nmol of peptide (Autospot Reference Handbook, Inta-
vis AG). Successful synthesis of each peptide was confirmed by bromphenol
blue staining of the membranes after each cycle. The CelluSpot glass slide
histone tail peptide array was purchased from Intavis AG, Germany.
Solid-Phase Peptide Synthesis
A variant of the MINT peptide containing only one lysine residue (A N S R S K R
G R S R N S A) was synthesized by following the Fmoc solid-phase peptide
synthesis and the synthesis was confirmed by mass spectrometry. The
sequence of the MINT peptide was modified to contain single target lysine in
order to follow the degree of methylation at the target lysine. Biotinylated
histone 3 peptide (residues 1–20) was purchased from JPT Peptide
Technologies.
Methylation of Peptide Arrays
The membranes containing 420 peptide spots were washed for 20 min in
methylation buffer containing 50 mM Tris/HCl (pH 9.0), 5 mM MgCl2, and
4 mM DTT and afterward incubated at ambient temperature for 45 min in
methylation buffer containing 20 nM SET7/9 enzyme and 0.76 mM labeled
[methyl-3H]-AdoMet (Perkin Elmer). The membranes were washed four times
with 50 mM NH4HCO3, dried between Whatman papers (Whatman GmbH,
Dassel, Germany), and rinsed with Amplify NAMP100V solution (GE Health-
care, Munich, Germany). The membranes were incubated on HyperfilmTM
high performance autoradiography films (GE Healthcare, Munich, Germany)
in the dark for 3–7 days. The films were developed using AGFA Curix 60
developing machine (Agfa Deutschland Vertriebsgesellschaft mbH & Co.
KG, Cologne, Germany) and the radioactive incorporation quantified usingier Ltd All rights reserved
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a similar way as described above.
In Vitro Methylation of Protein Domains
Protein domain methylation reactions were performed in methylation buffer
(50 mM Tris/HCl [pH 9.0], 5 mM MgCl2, 4 mM DTT) supplemented with
0.76 mM tritium-labeled AdoMet (specific activity: 2.7 TBq/mmol; Perkin
Elmer). Target proteins (2 mM) were incubated with 100 nM SET7/9 for
overnight at 37C. An aliquot of 10 ml of the reaction mixtures were loaded
on 12% SDS PAGE and separated and the amount of methylation was
detected by autoradiography.
Competitive Methylation of H3 and MINT Peptides
Two hundred nanomolar of biotinylated histone 3 (1-20) peptide and MINT
peptide variant containing only a single lysine residue were subjected to
competitive methylation in one reaction mixture with 10 nM SET7/9 enzyme
in methylation buffer (50 mM Tris/HCl [pH 9.0], 5 mM MgCl2, 4 mM DTT, and
200 mM AdoMet). The reaction was carried out at room temperature and
samples were collected from the reaction vial at different time points to check
the conversion of substrate peptides to mono- and dimethylated products.
The methylation status of the peptides was analyzed by mass spectrometry.
In Vitro Phosphorylation of Protein Domains
Protein domains (2 mM) were phosphorylated with 1000 units of cAMP-depen-
dent Protein Kinase (PKA) catalytic subunit (NEB, P6000S) for 2 hr at 30C in
50 mM Tris (pH 7.5), 10 mM MgCl2 supplemented with 123 nM [g-32P]-ATP
(specific activity 30 TBq/mmol; Hartmann Analytic GmbH). An aliquot of
20 ml of the reaction mixtures was loaded on 12% SDS PAGE and separated
and the amount of phosphorylation was detected by Phosphor Imager.
To study the interference of substrate protein phosphorylation on the meth-
ylation activity of SET7/9, the target proteins were phosphorylated in the
presence of unlabeled ATP (200 mM final concentration) as described above.
Afterward, the phosphorylated proteins were methylated using 100 nM
SET7/9 in the presence of 0.76 mM tritium-labeled AdoMet for 2 hr at 37C.
An aliquot of 10 ml of the reaction mixtures was loaded on 12% SDS PAGE,
separated and the amount of methylation was detected by autoradiography.
Cell Culture, Transfection, and Immunoprecipitation
The target protein domain constructs were transfected together with SET7/9
expression construct or without SET7/9 expression construct in HEK293 cells
using the transfection reagent FuGene6 (Roche) according to the manufac-
turer’s instructions. Two days after transfection, the nuclear extracts were
prepared as described (Andrews and Jones, 1991). Immunoprecipitation of
target protein domains in the nuclear extracts was performed by using Living
Colors Full-Length A.v. Polyclonal Antibody (Clontech) and Dynabeads Protein
G (Invitrogen) according to the manufacturers’ instructions.
Mass Spectrometry Analysis
The immunoprecipitated target protein domains were separated on 12%SDS-
PAGE and the bands of expected size were excised and further processed for
MALDImass spectrometric analysis using an Autoflex II device (Bruker Dalton-
ics) as described (Shevchenko et al., 2006). After overnight in gel digestion of
the target protein with 1 mg of Trypsin Gold (Promega) in a reaction volume of
50 ml, the peptides samples were diluted 1:5 with 0.1% TFA and subjected to
MALDI analysis as described below. In case of competitive methylation of H3
andMINT peptides, 1 ml of the reactionmixtures were diluted 1:10 in 0.1% TFA
and subjected to MALDI analysis as described below.
One microliter of the peptide dilution was applied to one spot on a prespot-
ted Anchorchip (PAC) HCCA Plate (Cat. No. 227463, Bruker Daltonics) and
washed with 10 mM sodium phosphate / 0.1% TFA solution. Spectra were re-
corded using an AutoFlex II (Bruker Daltonics, Bremen, Germany) with default
settings using peptide calibration standard mixture with the mass range of
1000 to 4000 Da (Cat. No. 206195, Bruker Daltonics) and processed using
the FlexAnalysis software (Bruker Daltonics). Protein methylation and phos-
phorylation was investigated using the Biotools program (Bruker Daltonics).
Methylated peptide peaks were not observed in protein domains purified
from E. coli. The corresponding masses could not be matched to any unmod-
ified full or partially digested peptide from the target proteins.Chemistry & Biology 18, 111SUPPLEMENTAL INFORMATION
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